Itgb3 (integrin subunit beta 3) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Itgb3 (integrin subunit beta 3) Rattus norvegicus
Symbol: Itgb3
Name: integrin subunit beta 3
RGD ID: 628868
Description: Contributes to fibrinogen binding activity. Involved in several processes, including positive regulation of cell migration; positive regulation of cell population proliferation; and positive regulation of signal transduction. Located in apical plasma membrane and cell surface. Part of integrin complex. Is active in glycinergic synapse. Colocalizes with focal adhesion. Biomarker of bacterial pneumonia; glomerulonephritis; and transient cerebral ischemia. Human ortholog(s) of this gene implicated in several diseases, including acute myeloid leukemia; autoimmune thrombocytopenic purpura; blood platelet disease (multiple); end stage renal disease; and non-arteritic anterior ischemic optic neuropathy. Orthologous to human ITGB3 (integrin subunit beta 3); PARTICIPATES IN integrin mediated signaling pathway; abciximab pharmacodynamics pathway; ephrin - ephrin receptor bidirectional signaling axis; INTERACTS WITH (+)-pilocarpine; 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine.
Type: protein-coding
Previously known as: GPIIIa; integrin beta 3; integrin beta 3 (Cd61); integrin beta-3; integrin, beta 3; platelet membrane glycoprotein IIIa
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21089,509,917 - 89,564,679 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1089,509,989 - 89,564,679 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1094,545,884 - 94,600,315 (+)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.01094,009,074 - 94,063,507 (+)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.01089,414,016 - 89,475,939 (+)NCBIRnor_WKY
Rnor_6.01092,667,869 - 92,783,413 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1092,667,869 - 92,783,410 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01092,424,545 - 92,538,859 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera1088,202,821 - 88,257,185 (+)NCBICelera
Cytogenetic Map10q32.1NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
Acute Coronary Syndrome  (ISO)
acute myeloid leukemia  (ISO)
Arterial Occlusive Diseases  (IMP)
arteriosclerosis  (ISO)
asthma  (ISO)
autism spectrum disorder  (ISO)
autistic disorder  (ISO)
autoimmune thrombocytopenic purpura  (ISO)
bacterial pneumonia  (IEP)
Banti's Syndrome  (ISO)
Bronchial Hyperreactivity  (ISO)
Carotid Artery Injuries  (IEP)
carotid artery thrombosis  (ISO)
carotid stenosis  (ISO)
Cerebral Hemorrhage  (ISO)
colorectal carcinoma  (ISO)
Coronary Disease  (ISO)
coronary thrombosis  (ISO)
diabetic retinopathy  (ISO)
end stage renal disease  (ISO)
Endotoxemia  (IMP)
Experimental Arthritis  (IMP)
Experimental Diabetes Mellitus  (IEP)
Experimental Liver Cirrhosis  (ISO)
Experimental Mammary Neoplasms  (IEP)
focal segmental glomerulosclerosis  (ISO)
genetic disease  (ISO)
Glanzmann Thrombasthenia 1  (ISO)
Glanzmann Thrombasthenia 2  (ISO)
Glanzmann's thrombasthenia  (ISO)
Gliosis  (ISO)
glomerulonephritis  (IEP,ISO)
Graves' disease  (ISO)
Hantavirus hemorrhagic fever with renal syndrome  (ISO)
Hantavirus Infections  (ISO)
Hemorrhage  (ISO)
hemorrhagic disease  (ISO)
Hip Fractures  (ISO)
lung disease  (ISO)
lung non-small cell carcinoma  (ISO)
myelodysplastic syndrome  (ISO)
myocardial infarction  (ISO)
Neonatal Alloimmune Thrombocytopenia  (ISO)
Neoplasm Metastasis  (ISO)
non-arteritic anterior ischemic optic neuropathy  (ISO)
Pathologic Constriction  (ISO)
Plaque, Atherosclerotic  (ISO)
platelet-type bleeding disorder 16  (ISO,ISS)
Platelet-Type Bleeding Disorder 24  (ISO)
pneumonia  (ISO)
Posttransfusion Purpura  (ISO)
Prostatic Neoplasms  (ISO)
Reperfusion Injury  (IMP)
Stroke  (IMP,ISO)
Sudden Cardiac Death  (ISO)
thrombocytopenia  (ISO)
Thrombocytopenic Purpura  (ISO)
Thrombotic Microangiopathies  (ISO)
transient cerebral ischemia  (IEP)
Ulcer  (ISO)
Venous Thrombosis  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-pilocarpine  (EXP)
(S)-nicotine  (ISO)
1,1-dichloroethene  (ISO)
1,2-dimethylhydrazine  (ISO)
1-naphthyl isothiocyanate  (EXP)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
3,3',5-triiodo-L-thyronine  (ISO)
3-Nitrobenzanthrone  (ISO)
4,4'-diaminodiphenylmethane  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxyphenyl retinamide  (ISO)
7,12-dimethyltetraphene  (ISO)
acetamide  (EXP)
acetylsalicylic acid  (ISO)
acrolein  (ISO)
aldehydo-D-glucose  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
apocynin  (ISO)
arachidonic acid  (ISO)
Arg-Gly-Asp  (ISO)
arsenous acid  (ISO)
atrazine  (ISO)
benzene-1,2,4-triol  (ISO)
benzo[a]pyrene  (ISO)
beryllium sulfate  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
butyric acid  (ISO)
C60 fullerene  (EXP)
cangrelor  (ISO)
cannabidiol  (EXP,ISO)
carbon disulfide  (ISO)
carbon nanotube  (ISO)
carmustine  (EXP,ISO)
chlordecone  (ISO)
chlorpyrifos  (ISO)
cisplatin  (ISO)
clomiphene  (ISO)
clopidogrel  (ISO)
cobalt dichloride  (ISO)
cocaine  (ISO)
curcumin  (EXP)
cycloheximide  (ISO)
cypermethrin  (EXP)
D-glucose  (ISO)
desferrioxamine B  (ISO)
dextran sulfate  (ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (ISO)
dibenziodolium  (ISO)
dibutyl phthalate  (ISO)
diclofenac  (ISO)
diethylstilbestrol  (EXP)
dimethylarsinous acid  (ISO)
ethanol  (ISO)
ethyl methanesulfonate  (ISO)
etoposide  (ISO)
fenofibrate  (EXP)
folic acid  (ISO)
geldanamycin  (ISO)
genistein  (EXP,ISO)
gentamycin  (EXP)
glucose  (ISO)
hydroquinone  (ISO)
hydroxysafflor yellow A  (EXP)
lead(0)  (ISO)
lead(2+)  (ISO)
leuprolide  (ISO)
lipopolysaccharide  (ISO)
LY294002  (ISO)
mancozeb  (ISO)
manganese(II) chloride  (ISO)
methyl methanesulfonate  (ISO)
methyllycaconitine  (ISO)
midostaurin  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
monosodium L-glutamate  (ISO)
N-acetyl-L-cysteine  (ISO)
N-formyl-L-methionyl-L-leucyl-L-phenylalanine  (ISO)
N-nitrosodimethylamine  (EXP)
nickel atom  (ISO)
nickel sulfate  (ISO)
niclosamide  (ISO)
nicotine  (ISO)
nitric oxide  (ISO)
nitroprusside  (ISO)
orphenadrine  (EXP)
ozone  (EXP)
paracetamol  (ISO)
pentane-2,3-dione  (EXP)
phorbol 13-acetate 12-myristate  (ISO)
pirinixic acid  (ISO)
potassium chromate  (ISO)
pregnenolone 16alpha-carbonitrile  (ISO)
progesterone  (ISO)
quercetin  (EXP,ISO)
quinoline  (ISO)
resveratrol  (ISO)
serotonin  (ISO)
sevoflurane  (ISO)
silicon dioxide  (ISO)
sodium arsenite  (EXP,ISO)
Sophoricoside  (ISO)
sotorasib  (ISO)
sulindac  (ISO)
tamoxifen  (ISO)
Tellimagrandin I  (ISO)
tert-butyl hydroperoxide  (EXP)
thioacetamide  (EXP)
thyroxine  (ISO)
titanium dioxide  (ISO)
trametinib  (ISO)
tranilast  (EXP)
triadimefon  (ISO)
trichloroethene  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
valproic acid  (ISO)
vinclozolin  (EXP)
vorinostat  (ISO)
wortmannin  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
activation of protein kinase activity  (IEA,ISO)
apolipoprotein A-I-mediated signaling pathway  (IEA,ISO)
apoptotic cell clearance  (IEA,ISO)
blood coagulation, fibrin clot formation  (IEA,ISO)
cell adhesion  (IEA,TAS)
cell adhesion mediated by integrin  (IEA,ISO)
cell-matrix adhesion  (IEA,ISO)
cell-substrate adhesion  (ISO)
cell-substrate junction assembly  (IEA,ISO)
cellular response to insulin-like growth factor stimulus  (IEP)
cellular response to mechanical stimulus  (IEP)
cellular response to platelet-derived growth factor stimulus  (IEA,ISO)
cellular response to xenobiotic stimulus  (IEP)
embryo implantation  (IEP)
heterotypic cell-cell adhesion  (IEA,ISO)
integrin-mediated signaling pathway  (IBA,IEA)
maintenance of postsynaptic specialization structure  (EXP,IDA)
mesodermal cell differentiation  (IEA,ISO)
negative chemotaxis  (IEA,ISO)
negative regulation of endothelial cell apoptotic process  (IMP)
negative regulation of lipid storage  (IEA,ISO)
negative regulation of lipid transport  (IEA,ISO)
negative regulation of lipoprotein metabolic process  (IEA,ISO)
negative regulation of low-density lipoprotein receptor activity  (IEA,ISO)
negative regulation of macrophage derived foam cell differentiation  (IEA,ISO)
platelet activation  (ISO)
platelet aggregation  (IEA,ISO)
platelet-derived growth factor receptor signaling pathway  (IEA,ISO)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway  (IMP)
positive regulation of angiogenesis  (IMP)
positive regulation of bone resorption  (IMP)
positive regulation of cell adhesion mediated by integrin  (IMP)
positive regulation of cell migration  (ISO)
positive regulation of cell-matrix adhesion  (IEA,ISO)
positive regulation of endothelial cell migration  (IEA,ISO)
positive regulation of endothelial cell proliferation  (IEA,ISO)
positive regulation of ERK1 and ERK2 cascade  (IMP)
positive regulation of fibroblast migration  (IEA,IMP,ISO)
positive regulation of fibroblast proliferation  (IEA,ISO)
positive regulation of gene expression  (IEA,ISO)
positive regulation of glomerular mesangial cell proliferation  (IMP)
positive regulation of leukocyte migration  (IMP)
positive regulation of osteoblast proliferation  (IEA,ISO)
positive regulation of peptidyl-tyrosine phosphorylation  (IEA,ISO)
positive regulation of smooth muscle cell migration  (IMP)
positive regulation of smooth muscle cell proliferation  (IMP)
positive regulation of substrate adhesion-dependent cell spreading  (IEA,ISO)
positive regulation of T cell migration  (IEA,ISO)
regulation of actin cytoskeleton organization  (IEA,ISO)
regulation of extracellular matrix organization  (IEA,ISO)
regulation of G protein-coupled receptor signaling pathway  (IMP)
regulation of postsynaptic neurotransmitter receptor diffusion trapping  (EXP,IDA)
regulation of postsynaptic neurotransmitter receptor internalization  (IEA,ISO)
regulation of protein localization  (IEA,ISO,ISS)
regulation of protein tyrosine kinase activity  (IEA,ISO)
regulation of release of sequestered calcium ion into cytosol  (IDA)
regulation of serotonin uptake  (IEA,ISO,ISS)
regulation of trophoblast cell migration  (IEA,ISO)
response to activity  (IEP)
response to platelet-derived growth factor  (IEP)
smooth muscle cell migration  (IEA,ISO)
substrate adhesion-dependent cell spreading  (IEA,ISO)
viral entry into host cell  (IEA)


References - curated
# Reference Title Reference Citation
1. Surgical injury enhances the expression of genes that mediate breast cancer metastasis to the lung. Al-Sahaf O, etal., Ann Surg. 2010 Dec;252(6):1037-43.
2. PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behcet's disease. Atzeni F, etal., Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S38-43. Epub 2011 Sep 27.
3. RGD-containing peptides inhibit fibrinogen binding to platelet alpha(IIb)beta3 by inducing an allosteric change in the amino-terminal portion of alpha(IIb). Basani RB, etal., J Biol Chem. 2001 Apr 27;276(17):13975-81. Epub 2001 Jan 18.
4. Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension. Bayan K, etal., J Thromb Thrombolysis. 2009 Jul;28(1):57-62. doi: 10.1007/s11239-008-0244-8. Epub 2008 Aug 7.
5. Structure and function of the platelet integrin alphaIIbbeta3. Bennett JS J Clin Invest. 2005 Dec;115(12):3363-9.
6. Integrins regulate opioid receptor signaling in trigeminal ganglion neurons. Berg KA, etal., Neuroscience. 2007 Feb 9;144(3):889-97. Epub 2006 Dec 8.
7. Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Bettaieb A, etal., Clin Exp Immunol. 1996 Jan;103(1):19-23.
8. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Boeri D, etal., Diabetes. 2001 Jun;50(6):1432-9.
9. Identification of an abnormal gene for the GPIIIa subunit of the platelet fibrinogen receptor resulting in Glanzmann's thrombasthenia. Bray PF and Shuman MA, Blood. 1990 Feb 15;75(4):881-8.
10. Inhibition of the intimal hyperplasia in an arterial autograft model by blockade of the N-terminal of the integrin beta3 subunit by monoclonal antibody P37. Bujan J, etal., Platelets. 1997;8(5):337-47.
11. Connection between integrins and cell activation in rat adrenal glomerulosa cells: a role for Arg-Gly-Asp peptide in the activation of the p42/p44(mapk) pathway and intracellular calcium. Campbell S, etal., Endocrinology. 2003 Apr;144(4):1486-95.
12. Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Carter AM, etal., Circulation. 1997 Sep 2;96(5):1424-31.
13. A crosstalk between β1 and β3 integrins controls glycine receptor and gephyrin trafficking at synapses. Charrier C, etal., Nat Neurosci. 2010 Nov;13(11):1388-95. doi: 10.1038/nn.2645. Epub 2010 Oct 10.
14. Platelet GP IIIA polymorphism HPA-1 (PLA1/2) is associated with hypertension as the primary cause for end-stage renal disease in hemodialysis patients from Greece. Chiras T, etal., In Vivo. 2009 Jan-Feb;23(1):177-81.
15. Beta3-integrin mediates smooth muscle cell accumulation in neointima after carotid ligation in mice. Choi ET, etal., Circulation. 2004 Mar 30;109(12):1564-9. Epub 2004 Mar 8.
16. Spironolactone increases integrin beta3 gene expression in kidney and heart muscle cells. Chun TY, etal., Mol Cell Endocrinol. 2002 Aug 30;194(1-2):175-82.
17. Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Crippes BA, etal., Endocrinology. 1996 Mar;137(3):918-24.
18. Comparative study of myelodysplastic syndromes and normal bone marrow biopsies with conventional staining and immunocytochemistry. Das R, etal., Anal Quant Cytol Histol. 2005 Jun;27(3):152-6.
19. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor. Ding G, etal., J Cereb Blood Flow Metab. 2005 Jan;25(1):87-97.
20. Coronary thrombosis and the platelet glycoprotein IIIA gene PLA2 polymorphism. Durante-Mangoni E, etal., Thromb Haemost. 1998 Aug;80(2):218-9.
21. Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins. Engebraaten O, etal., Anticancer Res. 2009 Jan;29(1):131-7.
22. Different biochemical expression pattern of platelet surface glycoproteins suggests molecular diversity of Glanzmann's thrombasthenia in Iran. Farsinejad A, etal., Blood Coagul Fibrinolysis. 2013 Sep;24(6):613-8. doi: 10.1097/MBC.0b013e328360a558.
23. Thrombophilic risk factors in the pathogenesis of non-arteritic anterior ischemic optic neuropathy patients. Felekis T, etal., Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):877-84. doi: 10.1007/s00417-010-1308-y. Epub 2010 Feb 17.
24. Natural history of platelet antibody formation against alphaIIbbeta3 in a French cohort of Glanzmann thrombasthenia patients. Fiore M, etal., Haemophilia. 2012 May;18(3):e201-9. doi: 10.1111/j.1365-2516.2011.02744.x. Epub 2012 Jan 18.
25. The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events. Galasso G, etal., BMC Cardiovasc Disord. 2010 Sep 16;10:41.
26. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
27. Identification of mimotopes of platelet autoantigens associated with autoimmune thrombocytopenic purpura. Gevorkian G, etal., J Autoimmun. 2000 Aug;15(1):33-40.
28. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
29. Higher prevalence of GPIIIa PlA2 polymorphism in siblings of patients with premature coronary heart disease. Goldschmidt-Clermont PJ, etal., Arch Pathol Lab Med. 1999 Dec;123(12):1223-9.
30. Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Gresele P, etal., Haematologica. 2009 May;94(5):663-9. doi: 10.3324/haematol.2008.002246. Epub 2009 Mar 31.
31. Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia. Guo L, etal., Blood. 2014 Jan 16;123(3):422-7. doi: 10.1182/blood-2013-08-523308. Epub 2013 Nov 20.
32. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Haas CS, etal., Arthritis Rheum. 2006 Aug;54(8):2402-14.
33. Distribution of alphavbeta3, alphavbeta5 integrins and the integrin associated protein--IAP (CD47) in human glomerular diseases. Hafdi Z, etal., Cell Adhes Commun. 2000;7(6):441-51.
34. Blockade of integrin beta3-FAK signaling pathway activated by osteopontin inhibits neointimal formation after balloon injury. Han M, etal., Cardiovasc Pathol. 2007 Sep-Oct;16(5):283-90. Epub 2007 Jun 20.
35. Integrins on rat osteoclasts: characterization of two monoclonal antibodies (F4 and F11) to rat beta 3. Helfrich MH, etal., J Bone Miner Res. 1992 Mar;7(3):345-51.
36. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. Hooper WC, etal., Chest. 1999 Oct;116(4):880-6.
37. Expression of integrin subunits alphav and beta3 in acute lung inflammation. Janardhan KS, etal., Histochem Cell Biol. 2004 May;121(5):383-90. Epub 2004 Apr 28.
38. Genetic variation in platelet integrin alphabeta (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma. Kallio JP, etal., BJU Int. 2006 Jul;98(1):201-4.
39. beta(1) and beta(3) integrins disassemble from basal focal adhesions and beta(3) integrin is later localised to the apical plasma membrane of rat uterine luminal epithelial cells at the time of implantation. Kaneko Y, etal., Reprod Fertil Dev. 2011;23(3):481-95.
40. Differential regulation of osteopontin receptors, CD44 and the alpha(v) and beta(3) integrin subunits, in the rat hippocampus following transient forebrain ischemia. Kang WS, etal., Brain Res. 2008 Sep 4;1228:208-16. Epub 2008 Jul 3.
41. Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. Kannan M, etal., J Thromb Haemost. 2009 Nov;7(11):1878-85. doi: 10.1111/j.1538-7836.2009.03579.x. Epub 2009 Aug 19.
42. Latent transforming growth factor-beta binding protein-1, a component of latent transforming growth factor-beta complex, accelerates the migration of aortic smooth muscle cells in diabetic rats through integrin-beta3. Kanzaki T and Otabe M, Diabetes. 2003 Mar;52(3):824-8.
43. Association of the platelet GPIIb/IIIa polymorphism with atherosclerotic plaque morphology: the Atherosclerosis Risk in Communities (ARIC) Study. Kucharska-Newton AM, etal., Atherosclerosis. 2011 May;216(1):151-6. doi: 10.1016/j.atherosclerosis.2011.01.038. Epub 2011 Feb 2.
44. P2Y nucleotide receptor signaling through MAPK/ERK is regulated by extracellular matrix: involvement of beta3 integrins. Kudirka JC, etal., J Cell Physiol. 2007 Oct;213(1):54-64.
45. Estrogen attenuates integrin-beta(3)-dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells. Li G, etal., Circulation. 2000 Jun 27;101(25):2949-55.
46. [The effect of mechanical stimulation on the expression of alpha 2, beta 1, beta 3 integrins and the proliferation, synthetic function in rat osteoblasts] Li L, etal., Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2003 Jun;20(2):187-92.
47. Intensity of platelet beta(3) integrin in patients with hemorrhagic fever with renal syndrome and its correlation with disease severity. Liu Z, etal., Viral Immunol. 2008 Jun;21(2):255-62.
48. Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer. Massabeau C, etal., Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):696-702. Epub 2009 Apr 20.
49. Genes that characterize T3-predominant Graves' thyroid tissues. Matsumoto C, etal., Eur J Endocrinol. 2013 Jan 17;168(2):137-44. doi: 10.1530/EJE-12-0507. Print 2013 Feb.
50. Platelet CD61 expression in vascular calcineurin inhibitor toxicity of renal allografts. Meehan SM, etal., Hum Pathol. 2008 Apr;39(4):550-6. doi: 10.1016/j.humpath.2007.08.012. Epub 2008 Jan 30.
51. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
52. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Miller PG, etal., Cancer Cell. 2013 Jul 8;24(1):45-58. doi: 10.1016/j.ccr.2013.05.004. Epub 2013 Jun 13.
53. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Moon C, etal., Respir Res. 2009 Mar 9;10:18.
54. The matricellular protein CCN5 regulates podosome function via interaction with integrin αvβ 3. Myers RB, etal., J Cell Commun Signal. 2014 Jun;8(2):135-46. doi: 10.1007/s12079-013-0218-2. Epub 2014 Feb 2.
55. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
56. Increased static pressure promotes migration of vascular smooth muscle cells: involvement of the Rho-kinase pathway. Onoue N, etal., J Cardiovasc Pharmacol. 2008 Jan;51(1):55-61.
57. Glanzmann's thrombasthenia associated with deletion-insertion and alternative splicing in the glycoprotein IIb gene. Peretz H, etal., Blood. 1995 Jan 15;85(2):414-20.
58. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
59. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
60. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
61. GOA pipeline RGD automated data pipeline
62. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
63. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
64. Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. Salter JW, etal., Am J Physiol Gastrointest Liver Physiol. 2001 Dec;281(6):G1432-9.
65. Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma. Sato T, etal., Anticancer Res. 2001 Jan-Feb;21(1B):643-7.
66. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. Scatena M, etal., J Cell Biol. 1998 May 18;141(4):1083-93.
67. Integrin receptor-mediated mobilisation of intranuclear calcium in rat osteoclasts. Shankar G, etal., J Cell Sci. 1993 May;105 ( Pt 1):61-8.
68. Quantification of epithelial cell differentiation in mammary glands and carcinomas from DMBA- and MNU-exposed rats. Sharma D, etal., PLoS One. 2011;6(10):e26145. doi: 10.1371/journal.pone.0026145. Epub 2011 Oct 12.
69. Cellular location of proteins related to iron absorption and transport. Simovich MJ, etal., Am J Hematol 2002 Mar;69(3):164-70.
70. In vivo characterization of the integrin beta3 as a receptor for Hantaan virus cellular entry. Song JW, etal., Exp Mol Med. 2005 Apr 30;37(2):121-7.
71. Demonstration of uterine receptivity in vitro by co-culture of rat epithelial cells and blastocyst. Srinivasan KR, etal., Cell Tissue Res. 2006 Jul;325(1):135-41. Epub 2006 Mar 10.
72. [Combined effects of platelet-derived growth factor-BB and insulin-like growth factor-I on the expression of integrin (beta 3 protein in periodontal ligament cells of rats during orthodontic tooth movement]. Su M, etal., Hua Xi Kou Qiang Yi Xue Za Zhi. 2011 Aug;29(4):409-12.
73. Involvement of osteopontin upregulation on mesangial cells growth and collagen synthesis induced by intermittent high glucose. Sun J, etal., J Cell Biochem. 2010 Apr 15;109(6):1210-21.
74. Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin. Sun J, etal., Mol Cell Endocrinol. 2009 Dec 10;313(1-2):64-9. Epub 2009 Aug 31.
75. Temporal response and localization of integrins beta1 and beta3 in the heart after myocardial infarction: regulation by cytokines. Sun M, etal., Circulation 2003 Feb 25;107(7):1046-52.
76. Prolonged exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the rat. Swain RA, etal., Neuroscience. 2003;117(4):1037-46.
77. The integrins. Takada Y, etal., Genome Biol. 2007;8(5):215.
78. Double heterozygosity for a novel missense mutation of Ile304 to Asn in addition to the missense mutation His280 to Pro in the integrin beta3 gene as a cause of the absence of platelet alphaIIbbeta3 in Glanzmann's thrombasthenia. Tanaka S, etal., J Thromb Haemost. 2005 Jan;3(1):68-73.
79. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Teeling JL, etal., Blood. 2001 Aug 15;98(4):1095-9.
80. Integrin beta 3 genotype influences asthma and allergy phenotypes in the first 6 years of life. Thompson EE, etal., J Allergy Clin Immunol. 2007 Jun;119(6):1423-9.
81. An in-vivo analysis of capillary stasis and endothelial apoptosis in a model of hypertension. Tran ED and Schmid-Schonbein GW, Microcirculation. 2007 Nov-Dec;14(8):793-804.
82. Glycoprotein IIB/IIIA-inhibition and microcirculatory alterations during experimental endotoxemia--an intravital microscopic study in the rat. Walther A, etal., Microcirculation. 2004 Jan-Feb;11(1):79-88.
83. Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Ward MR, etal., Atherosclerosis. 1998 Apr;137(2):267-75. doi: 10.1016/s0021-9150(97)00275-x.
84. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Wei C, etal., Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411.
85. Variation in ITGB3 is associated with asthma and sensitization to mold allergen in four populations. Weiss LA, etal., Am J Respir Crit Care Med. 2005 Jul 1;172(1):67-73. Epub 2005 Apr 7.
86. Beta3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed, hyperlipidemic mice. Weng S, etal., Proc Natl Acad Sci U S A. 2003 May 27;100(11):6730-5. Epub 2003 May 13.
87. Fibrinogen mediates platelet-polymorphonuclear leukocyte cooperation during immune-complex glomerulonephritis in rats. Wu X, etal., J Clin Invest. 1994 Sep;94(3):928-36.
88. Low-energy laser irradiation facilitates the velocity of tooth movement and the expressions of matrix metalloproteinase-9, cathepsin K, and alpha(v) beta(3) integrin in rats. Yamaguchi M, etal., Eur J Orthod. 2010 Apr;32(2):131-9. Epub 2010 Feb 16.
Additional References at PubMed
PMID:7525578   PMID:8601592   PMID:8837777   PMID:9553049   PMID:10022831   PMID:11606749   PMID:12204115   PMID:12807887   PMID:12867986   PMID:12900455   PMID:14681217   PMID:15031111  
PMID:15044441   PMID:15215180   PMID:15344881   PMID:15466936   PMID:15695822   PMID:16014375   PMID:16216233   PMID:16467530   PMID:16489109   PMID:16995821   PMID:17072743   PMID:17099249  
PMID:17483236   PMID:17665129   PMID:18256073   PMID:18441324   PMID:18549786   PMID:19027743   PMID:19122172   PMID:19141530   PMID:19234460   PMID:19359426   PMID:19461049   PMID:19578119  
PMID:19723805   PMID:19933311   PMID:20458337   PMID:20563599   PMID:20580365   PMID:20645409   PMID:20675382   PMID:20682778   PMID:20826760   PMID:21423176   PMID:21502139   PMID:21531996  
PMID:21559527   PMID:21670307   PMID:21792920   PMID:21932337   PMID:22027834   PMID:22178926   PMID:22227249   PMID:22505472   PMID:22915765   PMID:22984613   PMID:23023225   PMID:23125415  
PMID:23154389   PMID:23161541   PMID:23382103   PMID:23382219   PMID:23658023   PMID:23726972   PMID:23830386   PMID:24019890   PMID:24029230   PMID:24611720   PMID:24644077   PMID:24658351  
PMID:24928391   PMID:25063885   PMID:25300309   PMID:25389530   PMID:25911094   PMID:25974241   PMID:26494230   PMID:27235833   PMID:27842221   PMID:28097150   PMID:29038237   PMID:29800236  
PMID:30359790   PMID:30507047   PMID:31331973   PMID:31964805   PMID:32351169  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21089,509,917 - 89,564,679 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1089,509,989 - 89,564,679 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1094,545,884 - 94,600,315 (+)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.01094,009,074 - 94,063,507 (+)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.01089,414,016 - 89,475,939 (+)NCBIRnor_WKY
Rnor_6.01092,667,869 - 92,783,413 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1092,667,869 - 92,783,410 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01092,424,545 - 92,538,859 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera1088,202,821 - 88,257,185 (+)NCBICelera
Cytogenetic Map10q32.1NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh381747,253,827 - 47,313,743 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl1747,253,827 - 47,313,743 (+)EnsemblGRCh38hg38GRCh38
GRCh371745,331,193 - 45,391,109 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361742,686,207 - 42,745,076 (+)NCBINCBI36Build 36hg18NCBI36
Build 341742,686,206 - 42,745,076NCBI
Celera1741,781,276 - 41,840,192 (+)NCBICelera
Cytogenetic Map17q21.32NCBI
HuRef1740,709,287 - 40,768,167 (+)NCBIHuRef
CHM1_11745,396,156 - 45,455,032 (+)NCBICHM1_1
T2T-CHM13v2.01748,116,181 - 48,176,126 (+)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm3911104,498,826 - 104,561,302 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl11104,498,826 - 104,561,302 (+)EnsemblGRCm39 Ensembl
GRCm3811104,608,000 - 104,670,476 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl11104,608,000 - 104,670,476 (+)EnsemblGRCm38mm10GRCm38
MGSCv3711104,469,314 - 104,531,787 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv3611104,424,146 - 104,483,465 (+)NCBIMGSCv36mm8
Celera11116,336,310 - 116,392,711 (+)NCBICelera
Cytogenetic Map11E1NCBI
cM Map1167.84NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049554789,788,149 - 9,823,746 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049554789,788,192 - 9,830,254 (-)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan11719,665,154 - 19,725,956 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01710,134,450 - 10,194,596 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11710,353,111 - 10,388,924 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1710,353,111 - 10,392,382 (-)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.199,179,667 - 9,231,061 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl99,182,562 - 9,231,451 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha911,065,645 - 11,114,120 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0910,772,116 - 10,823,763 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl910,772,333 - 10,825,024 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.199,787,282 - 9,835,753 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0917,686,480 - 17,734,963 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0917,635,354 - 17,683,846 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440560216,320,810 - 16,379,027 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365412,815,738 - 2,871,035 (+)EnsemblSpeTri2.0
SpeTri2.0NW_0049365412,822,789 - 2,871,069 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl1216,693,514 - 16,752,292 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11216,694,466 - 16,752,228 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21216,718,915 - 16,775,379 (-)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.11659,372,171 - 59,431,434 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl1659,374,889 - 59,410,857 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366607730,082,743 - 30,143,493 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_0046248491,895,914 - 1,952,665 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046248491,895,378 - 1,952,755 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Itgb3
679 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:195
Count of miRNA genes:157
Interacting mature miRNAs:174
Prediction methods:Microtar, Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
61427Cia16Collagen induced arthritis QTL 163.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)10635789696121100Rat
2303118Mamtr7Mammary tumor resistance QTL 70.003mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)109658275104670812Rat
631268Cia21Collagen induced arthritis QTL 213.1joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1014487011104060283Rat
2316949Gluco60Glucose level QTL 603.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1014487011107057807Rat
1554317Bmd4Bone mineral density QTL 49.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)101981604299406971Rat
724556Pur2Proteinuria QTL 25.5urine protein amount (VT:0005160)urine protein level (CMO:0000591)102242750090627625Rat
61354Pia10Pristane induced arthritis QTL 100.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
631267Cia20Collagen induced arthritis QTL 203.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
61325Aia5Adjuvant induced arthritis QTL 50.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
1298069Bp168Blood pressure QTL 1685.5blood pressure trait (VT:0000183)systolic blood pressure (CMO:0000004)102652195798003205Rat
631542Bp82Blood pressure QTL 826.8arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)102652195798952741Rat
1331791Cm31Cardiac mass QTL 313.84606heart mass (VT:0007028)heart wet weight (CMO:0000069)1029299504107211142Rat
1576308Schws1Schwannoma susceptibility QTL 10.0041nervous system integrity trait (VT:0010566)percentage of study population developing trigeminal nerve neurilemmomas during a period of time (CMO:0002017)1040035094102359817Rat
631269Cia22Collagen induced arthritis QTL 228.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
631270Cia23Collagen induced arthritis QTL 233.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
1298078Stresp5Stress response QTL 52.990.00025blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)1042045676104670812Rat
2300218Hpcl2Hepatic cholesterol level QTL 2liver cholesterol amount (VT:0010498)liver cholesterol level (CMO:0001597)104502965095600334Rat
631547Bp87Blood pressure QTL 874.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)104736947092369470Rat
1549846Scl47Serum cholesterol level QTL 473.6blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)105057470795574707Rat
70364Bp72Blood pressure QTL 72arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)105112110096121100Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1051770177107211142Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)1051770177107211142Rat
1359017Hrtrt21Heart rate QTL 212.4heart pumping trait (VT:2000009)heart rate (CMO:0000002)105177294096772940Rat
631530Tls3T-lymphoma susceptibility QTL 300.0001thymus integrity trait (VT:0010555)percentage of study population developing T-cell lymphomas during a period of time (CMO:0001911)105177461295600334Rat
631535Cm51Cardiac mass QTL 513heart mass (VT:0007028)calculated heart weight (CMO:0000073)105178628291669536Rat
70171Cari1Carrageenan-induced inflammation QTL 14.90.0005hypodermis integrity trait (VT:0010550)inflammatory exudate volume (CMO:0001429)1053797385107211142Rat
70164Bw21Body weight QTL 214.360.00005body mass (VT:0001259)body weight (CMO:0000012)105379749498952626Rat
1354608Cm33Cardiac mass QTL 332.8heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)105480929299809292Rat
2312662Slep8Serum leptin concentration QTL 80.05blood leptin amount (VT:0005667)serum leptin level (CMO:0000780)1057134272102134272Rat
2312668Scl65Serum cholesterol level QTL 650.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)1057134272102134272Rat
2312672Insul15Insulin level QTL 150.01blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1057134272102134272Rat
1549831Bss6Bone structure and strength QTL 64lumbar vertebra strength trait (VT:0010574)vertebra ultimate force (CMO:0001678)1057576521102576521Rat
2293698Bss43Bone structure and strength QTL 435.330.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra cross-sectional area (CMO:0001689)1059209888104209888Rat
2306970Anxrr22Anxiety related response QTL 225.95fear/anxiety-related behavior trait (VT:1000241)number of periods of voluntary immobility (CMO:0001045)106134527698211570Rat
6893336Cm75Cardiac mass QTL 750.10.87heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)106134527699703528Rat
1558643Cm44Cardiac mass QTL 444.80.0000368heart mass (VT:0007028)heart wet weight (CMO:0000069)106134527699703528Rat
2313103Bss80Bone structure and strength QTL 8020.0001tibia strength trait (VT:1000284)tibia midshaft endosteal cross-sectional area (CMO:0001716)1062057807107057807Rat
2313105Bss79Bone structure and strength QTL 791.80.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)1062057807107057807Rat
61449Ciaa2CIA Autoantibody QTL 27.1blood autoantibody amount (VT:0003725)calculated serum anti-type 2 collagen antibody titer (CMO:0001279)1063221094107211142Rat
1357344Bp249Blood pressure QTL 2490.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)106674365598003205Rat
2317029Aia19Adjuvant induced arthritis QTL 192.98joint integrity trait (VT:0010548)left rear ankle joint diameter (CMO:0002149)1066978955107211142Rat
2317039Aia6Adjuvant induced arthritis QTL 64.31joint integrity trait (VT:0010548)right rear ankle joint diameter (CMO:0002150)1066978955107211142Rat
10450498Bp384Blood pressure QTL 3840.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1067750049107211142Rat
1642980Bp300Blood pressure QTL 300arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068383129107211142Rat
61396Bp9Blood pressure QTL 94.80.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068420376107211142Rat
2300172Bmd57Bone mineral density QTL 579.80.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1069738412107211142Rat
2293646Bss25Bone structure and strength QTL 2510.960.0001femur morphology trait (VT:0000559)femur cross-sectional area (CMO:0001661)1069738412107211142Rat
2293663Bss33Bone structure and strength QTL 339.340.0001femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)1069738412107211142Rat
6893366Bw106Body weight QTL 1060.30.47body mass (VT:0001259)body weight (CMO:0000012)1070199100107211142Rat
70193Mcs7Mammary carcinoma susceptibility QTL 72.38mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1072224939107211142Rat
2298548Neuinf7Neuroinflammation QTL 73.4nervous system integrity trait (VT:0010566)spinal cord RT1-B protein level (CMO:0002132)1072224939107211142Rat
2306793Ean5Experimental allergic neuritis QTL 54.7nervous system integrity trait (VT:0010566)IFNG-secreting splenocyte count (CMO:0002122)107255241693995749Rat
1358188Ept9Estrogen-induced pituitary tumorigenesis QTL 93.9pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)107345313696120911Rat
2292617Ept18Estrogen-induced pituitary tumorigenesis QTL 183.9pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)107345313696120911Rat
1579919Bp281Blood pressure QTL 2810.01arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107437208494965338Rat
10450495Bp383Blood pressure QTL 3830.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107624608594965338Rat
2292438Bp311Blood pressure QTL 311arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1076246085107211142Rat
1302404Cia27Collagen induced arthritis QTL 272.60.0045joint integrity trait (VT:0010548)experimental arthritis severity measurement (CMO:0001459)1076452683107211142Rat
4889492Pancm2Pancreatic morphology QTL 23.2pancreatic beta cell morphology trait (VT:0005217)ratio of insulin-positive cell area to total area of splenic region of pancreas (CMO:0001814)1076748906107211142Rat
1300107Rf18Renal function QTL 183.41urine output (VT:0003620)timed urine volume (CMO:0000260)107877551698279596Rat
631555Bp134Blood pressure QTL 1340.001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)108051528791230079Rat
6893357Bw102Body weight QTL 1020.50.36body mass (VT:0001259)body weight (CMO:0000012)1080515287101325465Rat
2303589Bw87Body weight QTL 872body mass (VT:0001259)body weight (CMO:0000012)1081285008107211142Rat
4889948Bss91Bone structure and strength QTL 914tibia area (VT:1000281)tibia midshaft total cross-sectional area (CMO:0001715)108256485692369470Rat
2317754Glom25Glomerulus QTL 253.5urine protein amount (VT:0005160)urine protein level (CMO:0000591)1082685200107211142Rat
12880055Am11Aortic mass QTL 110.004aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)108400727295933025Rat
2301398Kidm38Kidney mass QTL 380.002kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)108400727295933025Rat
2306792Ean4Experimental allergic neuritis QTL 44nervous system integrity trait (VT:0010566)IFNG-secreting splenocyte count (CMO:0002122)108402232193995963Rat
1600367Mcs15Mammary carcinoma susceptibility QTL 154.5mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1085565469103884409Rat
631538Oia5Oil induced arthritis QTL 5joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1087055121107211142Rat
2313856Bp342Blood pressure QTL 3424.40.0001life span trait (VT:0005372)age at time of death (CMO:0001193)108730761796121100Rat
61363Oia3Oil induced arthritis QTL 30.001joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1087307617107211142Rat
634320Niddm49Non-insulin dependent diabetes mellitus QTL 494.41blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1088539139107211142Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21089,534,945 - 89,535,132 (+)MAPPERmRatBN7.2
Rnor_6.01092,694,759 - 92,694,945NCBIRnor6.0
Rnor_5.01092,451,435 - 92,451,621UniSTSRnor5.0
Celera1088,228,983 - 88,229,169UniSTS
SHRSP x BN Map1068.71RGD
SHRSP x BN Map1068.71UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21089,564,943 - 89,565,094 (+)MAPPERmRatBN7.2
Rnor_6.01092,783,678 - 92,783,828NCBIRnor6.0
Rnor_5.01092,539,124 - 92,539,274UniSTSRnor5.0
RGSC_v3.41093,973,045 - 93,973,195UniSTSRGSC3.4
Celera1088,257,450 - 88,257,600UniSTS
RH 3.4 Map10973.8UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 1 10 35 35 11 35 11 11
Low 2 32 22 6 8 6 8 11 71 35 30 8
Below cutoff 1 3


Reference Sequences
RefSeq Acc Id: ENSRNOT00000073350   ⟹   ENSRNOP00000067271
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1089,509,989 - 89,564,679 (+)Ensembl
Rnor_6.0 Ensembl1092,667,879 - 92,783,410 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000082780   ⟹   ENSRNOP00000069911
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1089,518,278 - 89,564,679 (+)Ensembl
Rnor_6.0 Ensembl1092,667,869 - 92,707,000 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000112807   ⟹   ENSRNOP00000082658
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1089,526,090 - 89,564,679 (+)Ensembl
RefSeq Acc Id: NM_153720   ⟹   NP_714942
Rat AssemblyChrPosition (strand)Source
mRatBN7.21089,509,989 - 89,564,679 (+)NCBI
Rnor_6.01092,667,869 - 92,783,413 (+)NCBI
Rnor_5.01092,424,545 - 92,538,859 (+)NCBI
Celera1088,202,821 - 88,257,185 (+)RGD
RefSeq Acc Id: XM_039085714   ⟹   XP_038941642
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21089,509,917 - 89,558,325 (+)NCBI
Protein Sequences
Protein RefSeqs NP_714942 (Get FASTA)   NCBI Sequence Viewer  
  XP_038941642 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein CAD29521 (Get FASTA)   NCBI Sequence Viewer  
  Q8R2H2 (Get FASTA)   NCBI Sequence Viewer  
Reference Sequences
RefSeq Acc Id: NP_714942   ⟸   NM_153720
- Peptide Label: precursor
- UniProtKB: M0RCF3 (UniProtKB/Swiss-Prot),   Q8R2H2 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000069911   ⟸   ENSRNOT00000082780
RefSeq Acc Id: ENSRNOP00000067271   ⟸   ENSRNOT00000073350
RefSeq Acc Id: XP_038941642   ⟸   XM_039085714
- Peptide Label: isoform X1
RefSeq Acc Id: ENSRNOP00000082658   ⟸   ENSRNOT00000112807
Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q8R2H2-F1-model_v2 AlphaFold Q8R2H2 1-787 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13697823
Promoter ID:EPDNEW_R8347
Type:single initiation site
Description:integrin subunit beta 3
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database,
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.01092,667,842 - 92,667,902EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:628868 AgrOrtholog
BioCyc Gene G2FUF-23012 BioCyc
Ensembl Genes ENSRNOG00000048449 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000067271 ENTREZGENE, UniProtKB/TrEMBL
  ENSRNOP00000067271.3 UniProtKB/Swiss-Prot
  ENSRNOP00000069911.2 UniProtKB/TrEMBL
  ENSRNOP00000082658.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000073350 ENTREZGENE, UniProtKB/TrEMBL
  ENSRNOT00000073350.3 UniProtKB/Swiss-Prot
  ENSRNOT00000082780.2 UniProtKB/TrEMBL
  ENSRNOT00000112807.1 UniProtKB/TrEMBL
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  4.10.1240.30 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cytochrome c1, transmembrane anchor, C-terminal UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Laminin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ligand-binding face of the semaphorins, domain 2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ntegrin, alpha v. Chain A, domain 3 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro EGF_extracell UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  I-EGF_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_beta_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_bsu UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_bsu_cyt_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_bsu_tail UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_bsu_tail_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_bsu_VWA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PSI UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  vWFA_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:29302 UniProtKB/Swiss-Prot
PANTHER PTHR10082 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR10082:SF25 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam EGF_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  I-EGF_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_b_cyt UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_B_tail UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_beta UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PSI_integrin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Itgb3 PhenoGen
PIRSF Integrin_B UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE EGF_1 UniProtKB/Swiss-Prot
  EGF_2 UniProtKB/Swiss-Prot
  INTEGRIN_BETA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART INB UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_b_cyt UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Integrin_B_tail UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PSI UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP EGF/Laminin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Plexin repeat UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF53300 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF69179 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF69687 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ITB3_RAT UniProtKB/Swiss-Prot
UniProt Secondary M0RCF3 UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2015-12-23 Itgb3  integrin subunit beta 3  Itgb3  integrin, beta 3  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2009-12-15 Itgb3  integrin, beta 3  Itgb3  integrin beta 3  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2005-01-20 Itgb3  integrin beta 3    integrin beta 3 (Cd61)  Name updated 1299863 APPROVED
2003-02-27 Itgb3  integrin beta 3 (Cd61)      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_regulation activated along with integrin beta1 following myocardial infarction 633129